Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

»õ·ÎÀÌ Áø´ÜµÈ ¼Ò¾Æ °£Áú ȯÀÚ¿¡¼­ Topiramate ´Üµ¶ ¿ä¹ýÀÇ È¿´É¼º ¹× ¾ÈÀü¼º Safety and Efficacy of Topiramate Monotherapy in Children with Recent-onset Seizures

´ëÇÑ°£ÁúÇÐȸÁö 2001³â 5±Ç 1È£ p.65 ~ 69
¹Ú¿ì»ý, ±èâ¿ì, ¹Ú¼ºÆÄ, ±Ç¼øÇÐ,
¼Ò¼Ó »ó¼¼Á¤º¸
¹Ú¿ì»ý ( Park Woo-Saeng ) 
°æºÏ´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç

±èâ¿ì ( Kim Chang-Woo ) 
°æºÏ´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
¹Ú¼ºÆÄ ( Park Sung-Pa ) 
°æºÏ´ëÇб³ ÀÇ°ú´ëÇÐ ½Å°æ°úÇб³½Ç
±Ç¼øÇР( Kwon Soon-Hak ) 
°æºÏ´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç

Abstract

¸ñÀû: ¼Ò¾Æ °£Áú ȯÀÚ¿¡¼­ Topiramate ´Üµ¶ ¿ä¹ý¿¡ ´ëÇÑ Æò°¡´Â ±¹³»¿Ü¿¡ °ÅÀÇ º¸°íµÇÁö ¾Ê¾Æ ÀúÀÚµéÀº »õ·ÎÀÌ Áø´ÜµÈ ¼Ò¾Æ °£Áú ȯÀÚ¿¡¼­ Topiramate ´Üµ¶ ¿ä¹ý ½ÃÀÇ È¿´É¼º ¹× ¾ÈÁ¤¼º¿¡ ´ëÇÑ ÀÓ»óÀû Æò°¡¸¦ À§ÇØ º» ¿¬±¸¸¦ ½ÃÇàÇÏ¿´´Ù.

¹æ¹ý: ÀÌ ¿¬±¸´Â 2000³â 4¿ùºÎÅÍ 11¿ù±îÁö 8°³¿ù µ¿¾È °æºÏ´ëÇб³ º´¿ø ¼Ò¾Æ°ú¿¡ ¹æ¹®ÇÏ¿© »õ·ÎÀÌ Áø´ÜµÈ ¼Ò¾Æ °£Áú ȯÀÚ 54¸íÀ» ´ë»óÀ¸·Î ÀüÇâÀûÀ¸·Î °³¹æ¼º, ¹«ÀÛÀ§, ¾à¹° ºñ±³ ¿¬±¸¸¦ ½Ç½ÃÇÏ¿´´Ù.

°á°ú: Topiramate ´Üµ¶ ¿ä¹ýÀ» ½ÃÇàÇÑ 23¸íÁß °æ·ÃÀÇ ¿ÏÀü ¼Ò½Ç 64%, ÇöÀúÇÑ °³¼±(°æ·Ã °¨¼Ò°¡ 51~99%) 20%, °³¼±(°æ·Ã °¨¼Ò°¡ 26~50%) 8%, ºÒº¯(°æ·Ã °¨¼Ò°¡ 25%ÀÌÇÏ) 4%, ¾ÇÈ­(°æ·ÃÀÌ 25% ÀÌ»ó Áõ°¡) 4%À̾úÀ¸¸ç, Oxcarbazepine ´Üµ¶ ¿ä¹ýÀ» ½ÃÇàÇÑ 28¸íÁß ¿ÏÀü ¼Ò½Ç 59%, ÇöÀúÇÑ °³¼±(°æ·Ã °¨¼Ò°¡ 51~99%) 24%, °³¼±(°æ·Ã °¨¼Ò°¡ 26~50%) 10%, ºÒº¯(°æ·Ã °¨¼Ò°¡ 25%ÀÌÇÏ) 7%, ¾ÇÈ­(°æ·ÃÀÌ 25%ÀÌ»ó Áõ°¡)´Â ¾ø¾ú´Ù. ÇÏÁö¸¸ ÀÌµé µÎ ºñ±³±º»çÀÌ¿¡ È¿´É¼º(efficacy)¿¡ À־´Â Åë°èÇÐÀûÀ¸·Î Â÷ÀÌ°¡ ¾ø¾ú´Ù. ºÎÀÛ¿ëÀº °æ¹ÌÇÏ¿´À¸¸ç Áö¼ÓÀû Åõ¿©½Ã ¼Ò½ÇµÇ¾ú´Ù.

°á·Ð: »õ·ÎÀÌ Áø´ÜµÈ ¼Ò¾Æ °£Áú ȯÀÚ¿¡¼­ Topiramate ´Üµ¶ ¿ä¹ýÀº 64%¿¡¼­ °æ·ÃÀÇ ¿ÏÀü ¼Ò½ÇÀ» º¸¿´°í ½É°¢ÇÑ ºÎÀÛ¿ëÀÌ ³ªÅ¸³ªÁö ¾Ê¾Æ ¾ÆÁÖ È¿°úÀûÀÌ°í ¾ÈÀü¼ºÀÌ ³ôÀº Ä¡·á ¹æÆíÀ¸·Î »ý°¢µÈ´Ù.

Purpose: To investigate the efficacy and safety of topiramate monotherapy in children with recent-onset seizures.
Methods: An open-label, randomized, parallel group trial compared the efficacy and tolerability of topiramate monotherapy versus oxcarbazepine monotherapy in 54 children with newly diagnosed epilepsy.

Results: Of the 54 patients treated with topiramate (N=25) or oxcarbazepine (N=29), 51 patients completed the full study period of 16 weeks. In topiramate group, 64% became seizure free, 20% demonstrated a greater than 50% degree in seizure frequency, and 4% got worsened in seizure frequency. In oxcarbazepine group, 59% became seizure free, 24% experienced a greater than 50% reduction in seizure frequency. The efficacy was not statistically different between the two groups. Adverse events were usually only mild to moderate and the tolerability of therapy was similar between the two groups.

Conclusion: Topiramate monotherapy was highly effective in controlling seizures of children with newly diagnosed epilepsy (seizure free rate : 64%).

Å°¿öµå

Topiramate ´Üµ¶ ¿ä¹ý; »õ·ÎÀÌ Áø´ÜµÈ °£Áú
Topiramate monotherapy; Recent-onset seizures

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS